{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T16:53:40Z","timestamp":1791996820604,"version":"4.4.0"},"reference-count":98,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2019,9,30]],"date-time":"2019-09-30T00:00:00Z","timestamp":1569801600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100006492","name":"Division of Intramural Research, National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["1R01AI1269151"],"award-info":[{"award-number":["1R01AI1269151"]}],"id":[{"id":"10.13039\/100006492","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006492","name":"Division of Intramural Research, National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["5R01AI065617"],"award-info":[{"award-number":["5R01AI065617"]}],"id":[{"id":"10.13039\/100006492","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clin Experimental Allergy"],"published-print":{"date-parts":[[2020,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The Th2 cytokines interleukin 4 (IL\u20104) and IL\u201013 and the heterodimeric IL\u20104 receptor (IL\u20104R) complexes that they interact with play a key role in the pathogenesis of allergic disorders. Dupilumab is a humanized IgG4 monoclonal antibody that targets the IL\u20104 receptor alpha chain (IL\u20104R\u03b1), common to both IL\u20104R complexes: type 1 (IL\u20104R\u03b1\/\u03b3c; IL\u20104 specific) and type 2 (IL\u20104R\u03b1\/IL\u201013R\u03b11; IL\u20104 and IL\u201013 specific). In this review, we detail the current state of knowledge of the different signalling pathways coupled to the IL\u20104R complexes and examine the possible mechanisms of Dupilumab action and survey its clinical efficacy in different allergic disorders. The development of Dupilumab and the widening spectrum of its clinical applications is relevant to the current emphasis on precision medicine approaches to the blockade of pathways involved in allergic diseases.<\/jats:p>","DOI":"10.1111\/cea.13491","type":"journal-article","created":{"date-parts":[[2019,9,10]],"date-time":"2019-09-10T14:48:43Z","timestamp":1568126923000},"page":"5-14","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":489,"title":["Mechanisms of Dupilumab"],"prefix":"10.1111","volume":"50","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8218-2538","authenticated-orcid":false,"given":"Hani","family":"Harb","sequence":"first","affiliation":[{"name":"Division of Immunology Department of Pediatrics Boston Children\u2019s Hospital Harvard Medical School Boston MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7439-2762","authenticated-orcid":false,"given":"Talal A.","family":"Chatila","sequence":"additional","affiliation":[{"name":"Division of Immunology Department of Pediatrics Boston Children\u2019s Hospital Harvard Medical School Boston MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2019,9,30]]},"reference":[{"key":"e_1_2_14_2_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40348-016-0056-4"},{"key":"e_1_2_14_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2013.05.002"},{"key":"e_1_2_14_4_1","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2019.1595966"},{"key":"e_1_2_14_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cca.2018.09.024"},{"key":"e_1_2_14_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmed.2004.08.004"},{"key":"e_1_2_14_7_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01037"},{"key":"e_1_2_14_8_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20020903"},{"key":"e_1_2_14_9_1","doi-asserted-by":"publisher","DOI":"10.1086\/338242"},{"key":"e_1_2_14_10_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.immunol.17.1.701"},{"key":"e_1_2_14_11_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20020906"},{"key":"e_1_2_14_12_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1085458"},{"issue":"4","key":"e_1_2_14_13_1","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.4049\/jimmunol.161.4.1811","article-title":"Characterization of a mobile Stat6 activation motif in the human IL\u20104 receptor","volume":"161","author":"Ryan JJ","year":"1998","journal-title":"J Immunol"},{"key":"e_1_2_14_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2019.01.008"},{"key":"e_1_2_14_15_1","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/12.11.1499"},{"key":"e_1_2_14_16_1","doi-asserted-by":"publisher","DOI":"10.1189\/jlb.72.3.580"},{"key":"e_1_2_14_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(94)90356-5"},{"key":"e_1_2_14_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms3834"},{"key":"e_1_2_14_19_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0095432"},{"key":"e_1_2_14_20_1","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms14208"},{"key":"e_1_2_14_21_1","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.15.3.1778"},{"key":"e_1_2_14_22_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M116.746164"},{"key":"e_1_2_14_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2016.09.016"},{"key":"e_1_2_14_24_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20030471"},{"key":"e_1_2_14_25_1","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.aad6724"},{"key":"e_1_2_14_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2010.01.054"},{"key":"e_1_2_14_27_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20122239"},{"key":"e_1_2_14_28_1","doi-asserted-by":"publisher","DOI":"10.1038\/ni1544"},{"key":"e_1_2_14_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2007.12.030"},{"key":"e_1_2_14_30_1","doi-asserted-by":"publisher","DOI":"10.1038\/ni1506"},{"key":"e_1_2_14_31_1","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/dxl075"},{"key":"e_1_2_14_32_1","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/dxh312"},{"key":"e_1_2_14_33_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1003699"},{"key":"e_1_2_14_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2016.02.030"},{"key":"e_1_2_14_35_1","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.38269"},{"key":"e_1_2_14_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2014.04.013"},{"key":"e_1_2_14_37_1","doi-asserted-by":"publisher","DOI":"10.1038\/ni.3444"},{"key":"e_1_2_14_38_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature23469"},{"key":"e_1_2_14_39_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3004812"},{"key":"e_1_2_14_40_1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201410-1793OC"},{"key":"e_1_2_14_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2013.03.048"},{"key":"e_1_2_14_42_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20161274"},{"key":"e_1_2_14_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2017.08.046"},{"key":"e_1_2_14_44_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pbio.2005850"},{"key":"e_1_2_14_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2015.02.004"},{"key":"e_1_2_14_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2014.05.017"},{"key":"e_1_2_14_47_1","doi-asserted-by":"publisher","DOI":"10.1111\/cea.13161"},{"key":"e_1_2_14_48_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20161104"},{"key":"e_1_2_14_49_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.gene.6363746"},{"key":"e_1_2_14_50_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199712113372403"},{"key":"e_1_2_14_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0091-6749(99)70082-5"},{"key":"e_1_2_14_52_1","doi-asserted-by":"publisher","DOI":"10.1086\/302781"},{"key":"e_1_2_14_53_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20091480"},{"key":"e_1_2_14_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2016.06.003"},{"key":"e_1_2_14_55_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4147"},{"issue":"2","key":"e_1_2_14_56_1","first-page":"39","article-title":"MONOCLONAL ANTIBODY THERAPIES for atopic dermatitis: where are we now in the spectrum of disease management?","volume":"12","author":"Del Rosso JQ","year":"2019","journal-title":"J Clin Aesthet Dermatol"},{"key":"e_1_2_14_57_1","first-page":"1","article-title":"A review of dupilumab in the treatment of atopic diseases","author":"Thibodeaux Q","year":"2019","journal-title":"Hum Vaccin Immunother"},{"key":"e_1_2_14_58_1","unstructured":"Li\u2010Hsien WangYX MurphyA Sean Stevens Inventor.Regeneron Pharmaceuticals Inc assignee. Humanized IL\u20104 and IL\u20104R\u03b1 animals. 2012."},{"key":"e_1_2_14_59_1","unstructured":"Ana KosticLK LiuX ClassonBJ Allen Radin Inventor.Regeneron Pharmaceuticals Inc assignee. Methods for treating eosinophilic esophagitis by administering an il\u20104r inhibitor. 2016."},{"key":"e_1_2_14_60_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.93.1.231"},{"key":"e_1_2_14_61_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V91.10.3884"},{"key":"e_1_2_14_62_1","doi-asserted-by":"publisher","DOI":"10.1006\/jmbi.2001.5243"},{"key":"e_1_2_14_63_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2018.08.022"},{"key":"e_1_2_14_64_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11882-019-0849-3"},{"key":"e_1_2_14_65_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1700366"},{"key":"e_1_2_14_66_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31191-1"},{"key":"e_1_2_14_67_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.16156"},{"key":"e_1_2_14_68_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2014.10.013"},{"key":"e_1_2_14_69_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.14888"},{"key":"e_1_2_14_70_1","doi-asserted-by":"publisher","DOI":"10.2217\/imt.15.69"},{"key":"e_1_2_14_71_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.17869"},{"key":"e_1_2_14_72_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.02.053"},{"key":"e_1_2_14_73_1","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-3121"},{"key":"e_1_2_14_74_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2017.11.031"},{"key":"e_1_2_14_75_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.16317"},{"key":"e_1_2_14_76_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.18434"},{"key":"e_1_2_14_77_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.alit.2019.01.004"},{"key":"e_1_2_14_78_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1804092"},{"key":"e_1_2_14_79_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1804093"},{"key":"e_1_2_14_80_1","unstructured":"Pharmaceuticals R.Long\u2010term safety evaluation of dupilumab in patients with asthma (LIBERTY ASTHMA TRAVERSE). In."},{"key":"e_1_2_14_81_1","unstructured":"Pharmaceuticals R.Evaluation of dupilumab in children with uncontrolled asthma (VOYAGE). In:2019."},{"key":"e_1_2_14_82_1","unstructured":"Chatila WPaT.Effect of IL\u20104R\u03b1R576 polymorphism on response to dupilumab in adolescents and adults with asthma (I\u2010DAG). In:2019."},{"key":"e_1_2_14_83_1","doi-asserted-by":"publisher","DOI":"10.2147\/TCRM.S207402"},{"key":"e_1_2_14_84_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2015.10.010"},{"key":"e_1_2_14_85_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoto.2016.0678"},{"key":"e_1_2_14_86_1","doi-asserted-by":"publisher","DOI":"10.1111\/all.13685"},{"key":"e_1_2_14_87_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2019.03.023"},{"key":"e_1_2_14_88_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbalip.2016.07.014"},{"key":"e_1_2_14_89_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-08-520619"},{"key":"e_1_2_14_90_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-018-0314-6"},{"key":"e_1_2_14_91_1","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2019.1544893"},{"key":"e_1_2_14_92_1","doi-asserted-by":"publisher","DOI":"10.12688\/f1000research.11798.1"},{"key":"e_1_2_14_93_1","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.86355"},{"key":"e_1_2_14_94_1","unstructured":"Regeneron and sanofi announce positive phase 2 study results for dupilumab in patients with active moderate\u2010to\u2010severe eosinophilic esophagitis[press release].2017."},{"key":"e_1_2_14_95_1","doi-asserted-by":"publisher","DOI":"10.18176\/jiaci.0254"},{"key":"e_1_2_14_96_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2019.03.028"},{"key":"e_1_2_14_97_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2018.07.027"},{"key":"e_1_2_14_98_1","unstructured":"Pharmaceuticals R.Study in pediatric subjects with peanut allergy to evaluate the efficacy and safety of dupilumab as adjunct to AR101 (Peanut oral immunotherapy). 2018."},{"key":"e_1_2_14_99_1","unstructured":"Pharmaceuticals R.Study to evaluate the efficacy and safety of dupilumab monotherapy in pediatric patients with peanut. Allergy.2019."}],"container-title":["Clinical &amp; Experimental Allergy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fcea.13491","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cea.13491","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/cea.13491","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cea.13491","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,7]],"date-time":"2023-09-07T12:08:27Z","timestamp":1694088507000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/cea.13491"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,30]]},"references-count":98,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["10.1111\/cea.13491"],"URL":"https:\/\/doi.org\/10.1111\/cea.13491","archive":["Portico"],"relation":{},"ISSN":["0954-7894","1365-2222"],"issn-type":[{"value":"0954-7894","type":"print"},{"value":"1365-2222","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,30]]},"assertion":[{"value":"2019-06-28","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-09-03","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-09-30","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}